Patient characteristics by receipt of targeted therapy (yes/no) (2014–19 sensitivity analysis)
| Characteristic | PARPi and/or bevacizumab* | P value† | |
| Yes (n=1839) | No (n=1790) | ||
| Race and ethnicity | 0.371 | ||
| Non-Hispanic white | >1551 (>84.3) | >1479 (>82.6) | |
| Non-Hispanic black | 85 (4.6) | 96 (5.4) | |
| Asian | 73 (4.0) | 76 (4.2) | |
| Hispanic | 119 (6.5) | 128 (7.2) | |
| Other and unknown | <11 (0.6) | <11 (0.6) | |
| Marital status at diagnosis | 0.032 | ||
| Single | 122 (6.6) | 130 (7.3) | |
| Married | 602 (32.7) | 526 (29.4) | |
| Separated or divorced | 131 (7.1) | 113 (6.3) | |
| Widowed | 252 (13.7) | 309 (17.3) | |
| Unmarried or domestic partner | <11 (0.6) | <11 (0.6) | |
| Unknown | >721 (>39.2) | >701 (>39.2) | |
| Age group at diagnosis (years) | <0.001 | ||
| 65–69 | 518 (28.2) | 373 (20.8) | |
| 70–74 | 620 (33.7) | 495 (27.7) | |
| 75–79 | 386 (21.0) | 442 (24.7) | |
| 80–84 | 212 (11.5) | 289 (16.1) | |
| ≥85 | 103 (5.6) | 191 (10.7) | |
| Year of diagnosis | 0.015 | ||
| 2014 | 287 (15.6) | 328 (18.3) | |
| 2015 | 334 (18.2) | 363 (20.3) | |
| 2016 | 324 (17.6) | 319 (17.8) | |
| 2017 | 327 (17.8) | 271 (15.1) | |
| 2018 | 303 (16.5) | 248 (13.9) | |
| 2019 | 264 (14.4) | 261 (14.6) | |
| Cancer stage | 0.260 | ||
| Stage III | 643 (35.0) | 658 (36.8) | |
| Stage IV | 1196 (65.0) | 1132 (63.2) | |
| Region at diagnosis | 0.004 | ||
| Midwest | 98 (5.3) | 140 (7.8) | |
| Northeast | 628 (34.1) | 651 (36.4) | |
| South | 531 (28.9) | 477 (26.6) | |
| West | 582 (31.6) | 522 (29.2) | |
| Rurality | 0.323 | ||
| Metropolitan | 1581 (86.0) | 1560 (87.2) | |
| Urban | 233 (12.7) | 214 (12.0) | |
| Rural | 25 (1.4) | 16 (0.9) | |
| Charlson Comorbidity Index | <0.001 | ||
| 0 | 1169 (63.6) | 1028 (57.4) | |
| 1 | 384 (20.9) | 384 (21.5) | |
| ≥2 | 286 (15.6) | 378 (21.1) | |
| YOST index‡ | 0.691 | ||
| Quintile 1–2 | 441 (24.0) | 439 (24.5) | |
| Quintile 3–5 | 1346 (73.2) | 1308 (73.1) | |
| Unknown | 52 (2.8) | 43 (2.4) | |
*Percentages may not add up to 100% secondary to rounding.
†P values derived from χ2 tests.
‡YOST index is a census tract-level socioeconomic status variable that includes median household income, median house value, median rent, per cent <150% of poverty line, education index, per cent working class, and per cent unemployed.19 20 YOST index was dichotomized into low socioeconomic status (quintiles 1–2) and high socioeconomic status (quintiles 3–5).
PARPi, poly ADP-ribose polymerase inhibitor.